linjc16/ctgov huggingface dataset:
Immediate Load of Dental Implants, Placed in Atrophic Upper and/or Lower Jaw of Partial or Complete Edentate Patients, According to Flapless Technique

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the placement of implants with minimal invasive techniques. Immediately after the placement of the implants, functional loaded synthetic teeth will be placed.

Official Title
-----------------
Immediate Load of Dental Implants, Placed in Atrophic Upper and/or Lower Jaw of Partial or Complete Edentate Patients, According to Flapless Technique

Conditions
-----------------
Dental Implants

Intervention / Treatment
-----------------
* Procedure: Placement of functional loaded synthetic teeth after placement implants


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Implants<br> | Procedure: Placement of functional loaded synthetic teeth after placement implants<br>* Placement of functional loaded synthetic teeth after placement implants<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant success at 0-3 years |  | At 0-3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prosthetic success |  | At the moment | 
| Patient opinion |  | At same day |
Pilot Study of the Effect of Baclofen and Bromocriptine on Luteinizing Hormone Secretion in Pubertal Children

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate the effect of bromocriptine on luteinizing hormone (LH) secretion by suppression of prolactin and stimulation of dopaminergic receptors in early pubertal boys and girls. II. Evaluate the effect of baclofen on LH secretion by stimulation of gamma-aminobutyric acid receptors in early pubertal boys and girls.

Detailed Description
-----------------
PROTOCOL OUTLINE: Participants receive bromocriptine or baclofen followed by nocturnal measurements of luteinizing hormone, growth hormone, and sex steroids. Pituitary reserve is evaluated with the administration of gonadotropin-releasing hormone, and in children undergoing assessment of short stature, standard provocative stimuli.

Conditions
-----------------
Growth Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Short stature and/or constitutional growth delay No epilepsy or risk of epilepsy

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
constitutional growth delay, endocrine disorders, rare disease
Correlation Between Various Inflammatory Markers and Vascular Inflammation Measured by 18FDG-PET

Study Overview
=================
Brief Summary
-----------------
Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. Various inflammatory markers such as LpPLA2,MCP-2 and hsCRP are well-known prognostic factors for the cardiovascular event. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.Therefore, the purpose of the study is to demonstrate the correlation between various inflammatory markers and vascular inflammation detected by 18FDG-PET.

Official Title
-----------------
Correlation of Inflammatory Markers Such as LpPLA2,MCP-1 and hsCRP for Predicting Vascular Inflammation; Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography

Conditions
-----------------
Atherosclerosis

Intervention / Treatment
-----------------
* Other: Cross section study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy patients for visiting routine medical check in our clinic Exclusion Criteria: History of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization) Diabetes Stage 2 hypertension (resting blood pressure, ≥160/100 mmHg) Malignancy Severe renal or hepatic disease Subjects taking medications that might affect inflammation such as NSIAD and statin

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 88 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy patients<br> | Other: Cross section study<br>* This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between various inflammatory markers including LpPLA2,MCP-1 and hsCRP and vascular inflammation analyzed by 18FDG-PET |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between various inflammatory markers and atherosclerosis measured by carotid intima media thickness |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atherosclerosis, vascular inflammation, LpPLA2, hsCRP, MCP-1, 18FDG-PET
Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Study Overview
=================
Brief Summary
-----------------
The purpose of the investigation is to confirm the following under the post-marketing actual use of Forxiga Tablets (hereinafter referred to as Forxiga) in elderly patients. Development of ADRs specified as Key Investigation Items and the risk factors Contributing factors possibly having an impact on the safety and efficacy Development of ADRs unexpected from the Precautions for use and ADRs under actual drug use

Official Title
-----------------
Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Conditions
-----------------
Type 2 Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated with Forxiga for the first time during three months after the launch due to type 2 diabetes mellitus, which is the indication of the drug, aged 65 or over at the time when Forxiga was started. In addition, patients receiving the study drug of Forxiga before the launch should be included also. Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event incidence |  | from baseline to 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 diabetes mellitus, Diabetes, Forxiga, Elderly
Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
The objectives of the study are to assess the safety and tolerability of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects, to determine the pharmacokinetic profile and pharmacodynamics effects of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects.

Official Title
-----------------
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Administered Orally as Single Doses to Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: IW-1701
* Drug: Matching Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Between 18 and 60 years old at the Screening Visit; Women of childbearing potential must have a negative pregnancy test and must agree to use double-barrier contraception; BMI > 18.5 and < 32.0 kg/m2 at the Screening Visit; In overall good health with no clinically significant laboratory, ECG, or physical exam findings; Other inclusion criteria per protocol. Exclusion: History of any clinically-significant medical condition; Other exclusion criteria per protocol.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IW-1701<br>Single Dose | Drug: IW-1701<br> <br> |
| Placebo Comparator: Matching Placebo for IW-1701<br>Single Dose | Drug: Matching Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the safety and tolerability of IW-1701 in healthy subjects via adverse events | The primary objectives of this study are to assess the safety and tolerability of single ascending dosage levels of IW-1701 versus placebo in healthy subjects. | From baseline up to 8 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy Subjects
Segmental Epidural Block for Feeding Jeujunostomy in Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This study aim is to compare the efficiency and safety of segmental epidural block versus general anesthesia in cancer patients undergoing surgical feeding jejunostomy

Detailed Description
-----------------
Comparing general anesthesia versus segmental epidural anesthesia in feeding jejunostomy

Official Title
-----------------
Segmental Epidural Block for Feeding Jejunostomy in Cancer Patients

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Procedure: Epidural anesthesia
* Procedure: general anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for surgical feeding jejunostomy more than 18 years old Exclusion Criteria: patien refusal Coagulation defect Abnormal kidney or liver functions Local infection at site of block Bone metastases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: General anesthesia<br>Patients will receive general anesthesia | Procedure: general anesthesia<br>* general anesthesia<br>|
| Experimental: Epidural anesthesia<br>Patients will receive epidural anesthesia | Procedure: Epidural anesthesia<br>* Segmental epidural analgesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analgesic requirements | Analgesic requirments | first 24 hours | 
| Haemodynamics | blood pressure | periooperative time | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS score | visual analouge scale 0 minimum to 10 maximum score | 24 hours |
Tranexamic Acid in Urologic Surgery

Study Overview
=================
Brief Summary
-----------------
This prospective randomized double-blind placebo vs control study aims at verifying the efficacy of tranexamic acid administration in reducing perioperative bleeding in patients undergoing open radical prostatectomy. Two recent meta-analysis confirmed that tranexamic acid administration does not increase mortality, myocardial infarction, deep venous thrombosis, pulmonary embolism, stroke and renal failure. 200 patients undergoing open radical prostatectomy will be enrolled. Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion. Patients belonging to the control group will receive the same volume of saline infusions.

Official Title
-----------------
Efficacy of Tranexamic Acid in Reducing Perioperative Bleeding in Patients Undergoing Radical Prostatectomy. A Randomized Controlled Double-blind Study.

Conditions
-----------------
Bleeding, Prostatectomy

Intervention / Treatment
-----------------
* Drug: Tranexamic Acid
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients Patients undergoing open radical prostatectomy Exclusion Criteria: Age < 18 years Patients with drug eluting stent with a double antiplatelet therapy Atrial fibrillation Thrombophilic diathesis Allergy to tranexamic acid

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion. | Drug: Tranexamic Acid<br>* Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.<br>* Other names: UGUROL;|
| Placebo Comparator: 2<br>Patients belonging to the control group will receive the same volume of saline infusions. | Drug: Placebo<br>* Patients belonging to the control group will receive the same volume of saline infusions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tranexamic acid, prostatectomy, surgery
Response Evaluation in Malignant Pleural Mesothelioma

Study Overview
=================
Brief Summary
-----------------
Recently, a few small trials have shown promising results on value of fluoro-2-deoxy-D-glucose and positron emission tomography imaging in response assessment in Malignant Pleural Mesothelioma. These studies considered different parameters in Positron Emission Tomography (PET) analysis, mainly the standardized uptake value and volume-based parameters such as total glycolytic volume.

Detailed Description
-----------------
This is a retrospective analysis of two consecutive and homogeneous series of Malignant Pleural Mesothelioma patients treated with first-line pemetrexed-based chemotherapy and evaluated by CT scan and FDG-PET.

Official Title
-----------------
Early Response Evaluation in Malignant Pleural Mesothelioma By Total Glycolytic Volume (TGV) Analysis of Serial FDG-PET Scans (Positron Emission Tomography Scans)

Conditions
-----------------
Malignant Pleural Mesothelioma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically proven MALIGNANT PLEURAL MESOTHELIOMA Patients not candidate to radical surgery Unidimensionally and/or bidimensionally CT-measurable disease and Candidate to first-line pemetrexed-based chemotherapy Exclusion Criteria: Histologically not proven MALIGNANT PLEURAL MESOTHELIOMA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To validate a semi-automated iterative threshold-based region growing algorithm in a previously published series of patients. |  | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To extend the analysis to another series of consecutive patients with MALIGNANT PLEURAL MESOTHELIOMA treated with first-line pemetrexed-based chemotherapy, and to perform a combined analysis of the two groups. |  | 4 months | 
| To validate the new liver-based threshold semi-automated algorithm on the GE ADW4.6 workstation with the algorithm validated in step 1 in the same subset of patients. |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Histologically proven of Malignant pleural mesothelioma;, Patients not candidate to radical surgery;, Candidate to first-line pemetrexed-based chemotherapy;
NovoLet® Surveillance Study on Using Human Insulin System in Indonesia

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.

Official Title
-----------------
A Post Marketing Surveillance on the Use of NovoLet® Human Insulin System in Indonesia

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: biphasic human insulin
* Drug: isophane human insulin
* Drug: human soluble insulin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 diabetes mellitus Type 2 diabetes mellitus Other types of diabetes mellitus (gestational, drug induced [thiazide] or metabolic syndrome-related)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NovoLet® device<br> | Drug: biphasic human insulin<br>* NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator<br>Drug: isophane human insulin<br>* NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator<br>Drug: human soluble insulin<br>* NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in body weight |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fasting blood glucose (FBG) |  |  | 
| 2 hours postprandial blood glucose (2-hr PPBG) |  |  | 
| HbA1c (glycosylated haemoglobin) |  |  | 
| Adverse events (AEs) including hypoglycaemic episodes |  |  |
Photodynamic Therapy (PDT) Versus Transpupillary Thermotherapy (TTT) in Occult Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (AMD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effect of PDT and TTT for the treatment of subfoveal occult CNV in age-related macular degeneration.

Official Title
-----------------
Photodynamic Therapy Versus Transpupillary Thermotherapy in Occult CNV in Age-related Macular Degeneration

Conditions
-----------------
Age-Related Macular Degeneration

Intervention / Treatment
-----------------
* Procedure: laser treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 55 years of age, Subfoveal occult only CNV due to AMD, < 4 disc areas or > 4 disc areas VA < 0.4 Exclusion Criteria: Sign of classic CNV, CNV in other diagnoses than AMD,

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: laser treatment|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |